Account
Inquiry
QSC tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This synthetic peptide mimics the action of endogenous incretins to enhance insulin secretion while suppressing glucagon levels, making it valuable for metabolic research applications.
The compound features a 39-amino acid peptide backbone with strategic modifications including two non-natural residues (Aib at positions 2 and 13) and a C20 fatty diacid side chain at Lys20. These structural elements contribute to its extended half-life of approximately 117 hours, providing sustained biological activity.
For research purposes, qsc tirzepatide is typically administered in weekly subcutaneous doses. The standard research protocol begins with 2.5mg doses, potentially escalating to maintenance levels of 5-15mg based on experimental requirements. Maximum research doses should not exceed 15mg weekly.
Our pharmaceutical-grade qsc tirzepatide is produced under strict GMP conditions with comprehensive quality control measures including HPLC purity verification, mass spectrometry analysis, and amino acid sequencing. The product is supplied as lyophilized powder in sterile vials with rubber stoppers and aluminum seals to maintain stability.
Key research applications for qsc tirzepatide include: metabolic syndrome studies, glucose homeostasis research, weight management mechanisms, and incretin hormone pathway investigations. The compound has shown particular promise in studies of obesity-related metabolic disorders.
Storage recommendations: Maintain unopened vials at 2-8°C protected from light. Reconstituted solutions should be used immediately or stored at 2-8°C for no more than 24 hours. Always follow proper laboratory handling procedures when working with peptide compounds.
